EuroPCR 2021: Late-Breaking Science Collection
Published: 22 June 2021
-
Views:
1304
-
Likes:
7
-
Views:
1304
-
Likes:
7
-
Up Next -
10m 17sPart 2 | Session 3 The EBC Main Study: Dr David Hildick-Smith
-
7m 3sPart 2 | Session 4 2V-TAVR: Dr Uri Landes
-
4m 29sPart 2 | Session 5 The TriClip bRIGHT Study: Prof Philipp Lurz
-
4m 10sPart 2 | Session 6 The EFFECTIVENES Trial: Prof Philipp Lurz
-
4m 26s
-
7m 30sPart 2 | Session 8 TAVR for BAV Stenosis in Low Surgical Risk Patients: Dr Raj Makkar
-
9m 49sPart 2 | Session 9 2-year Results from the MAGSTEMI Trial: Dr Luis Ortega-Paz
-
3m 33sPart 2 | Session 10 Results from the Early Neo2 Registry: Dr Andreas Rück
-
8m 8sPart 2 | Session 11 Findings From the POEM Study: Dr Giulio Stefanini
-
5m 59sPart 2 | Session 12 The Portico™ NG Study: Prof Lars Søndergaard
-
6m 35sPart 2 | Session 13 Drug coated Balloons vs Drug Eluting Stents: Dr Upul Wickramarachchi
-
26m 20sPart 1 View From the Thoraxcenter: Wrap Up of EuroPCR 2021 Nicolas M Van Mieghem, Joost Daemen
-
5m 55sPart 2 | Session 1 Late Stroke after TAVI: Dr Henrik Bjursten Henrik Bjursten
Overview
In part 1 of this video series, Prof Nicolas Van Mieghem and Dr Joost Daemen host our review series View from the Thoraxcenter. This provides a concise analysis of the highlights of EuroPCR 2021’s Late-Breaking Trials.
The Expert Interviews featured in part 2 provide a short, accessible overview of some selected trials presented at EuroPCR 2021. These videos focus on each study’s design, results and impact on future practice. Some highlights of these interviews include an overview of the Portico™ NG study from Prof Lars Søndergaard and an insightful discussion of TAVR for Bicuspid Aortic Valve Stenosis in a low-risk patient population by Dr Raj Makkar.
More from this programme
Part 1
View from the Thoraxcenter: Wrap Up
Part 2